CN110031626A - A kind of marker ACK1 and its application for gastrointestinal stromal tumors migration - Google Patents
A kind of marker ACK1 and its application for gastrointestinal stromal tumors migration Download PDFInfo
- Publication number
- CN110031626A CN110031626A CN201910261493.7A CN201910261493A CN110031626A CN 110031626 A CN110031626 A CN 110031626A CN 201910261493 A CN201910261493 A CN 201910261493A CN 110031626 A CN110031626 A CN 110031626A
- Authority
- CN
- China
- Prior art keywords
- cell
- ack1
- gist
- migration
- marker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 title claims abstract description 55
- 102100036409 Activated CDC42 kinase 1 Human genes 0.000 title claims abstract description 44
- 101000928956 Homo sapiens Activated CDC42 kinase 1 Proteins 0.000 title claims abstract description 44
- 230000005012 migration Effects 0.000 title claims abstract description 19
- 238000013508 migration Methods 0.000 title claims abstract description 19
- 239000003550 marker Substances 0.000 title claims abstract description 12
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 title claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 27
- 201000009030 Carcinoma Diseases 0.000 claims abstract description 3
- 230000004913 activation Effects 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 229920002684 Sepharose Polymers 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 230000004709 cell invasion Effects 0.000 claims description 9
- 108010082117 matrigel Proteins 0.000 claims description 9
- 238000001262 western blot Methods 0.000 claims description 9
- 239000001963 growth medium Substances 0.000 claims description 8
- 230000029663 wound healing Effects 0.000 claims description 8
- 238000009835 boiling Methods 0.000 claims description 6
- 238000005119 centrifugation Methods 0.000 claims description 6
- 238000000749 co-immunoprecipitation Methods 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000012160 loading buffer Substances 0.000 claims description 6
- 239000012139 lysis buffer Substances 0.000 claims description 6
- 239000012679 serum free medium Substances 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 4
- 238000004043 dyeing Methods 0.000 claims description 4
- 238000011534 incubation Methods 0.000 claims description 4
- 239000013078 crystal Substances 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 238000001502 gel electrophoresis Methods 0.000 claims description 3
- 238000003384 imaging method Methods 0.000 claims description 3
- 238000004020 luminiscence type Methods 0.000 claims description 3
- 239000006166 lysate Substances 0.000 claims description 3
- 230000002101 lytic effect Effects 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 claims description 3
- 238000011002 quantification Methods 0.000 claims description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 3
- 238000007711 solidification Methods 0.000 claims description 3
- 230000008023 solidification Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 1
- 238000007689 inspection Methods 0.000 claims 1
- 150000002739 metals Chemical class 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 42
- 230000005764 inhibitory process Effects 0.000 abstract description 11
- 210000001519 tissue Anatomy 0.000 abstract description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract description 3
- 125000000539 amino acid group Chemical group 0.000 abstract description 3
- 210000000349 chromosome Anatomy 0.000 abstract description 3
- 210000000805 cytoplasm Anatomy 0.000 abstract description 3
- 206010017758 gastric cancer Diseases 0.000 abstract description 3
- 201000005202 lung cancer Diseases 0.000 abstract description 3
- 208000020816 lung neoplasm Diseases 0.000 abstract description 3
- XNFHHOXCDUAYSR-SFHVURJKSA-N n-[[(2s)-oxolan-2-yl]methyl]-5,6-diphenylfuro[2,3-d]pyrimidin-4-amine Chemical compound C([C@H]1OCCC1)NC(C1=2)=NC=NC=2OC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 XNFHHOXCDUAYSR-SFHVURJKSA-N 0.000 abstract description 3
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 abstract description 3
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 abstract description 3
- 201000011549 stomach cancer Diseases 0.000 abstract description 3
- 108091005703 transmembrane proteins Proteins 0.000 abstract description 3
- 102000035160 transmembrane proteins Human genes 0.000 abstract description 3
- 230000004614 tumor growth Effects 0.000 abstract description 3
- 239000003112 inhibitor Substances 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 description 5
- 230000035772 mutation Effects 0.000 description 4
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 4
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 2
- 102000001892 Protein Kinase C-theta Human genes 0.000 description 2
- 108010015499 Protein Kinase C-theta Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 102100022992 Anoctamin-1 Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 101000757261 Homo sapiens Anoctamin-1 Proteins 0.000 description 1
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 description 1
- 101150038994 PDGFRA gene Proteins 0.000 description 1
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 description 1
- 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000005769 single-targeted inhibition Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
One kind being used for gastrointestinal stromal tumor (Gastrointestinal stromal tumors, GIST) the marker ACK1 of diagnosing tumor and migration, the marker has following two feature: (1) with Carcinoma side normal tissue compared with, ACK1 high expression and activation in GIST cell；(2) targeted inhibition ACK1 can inhibit the migration of GIST cell, and ACK1 is a kind of nonreceptor tyrosine kinase, be located at cytoplasm, the received extracellular signal of main conduction transmembrane protein to downstream passages,ACK1Gene is located at No. 3 chromosomes 29, it encodes albumen and contains 1091 amino acid residues, molecular weight is 145 kDa, high expression of the ACK1 in the kinds of tumor such as gastric cancer, lung cancer and to tumour growth, migration and in terms of from important function, AIM-100 is the selectively targeted inhibitor of ACK1.
Description
Technical field
The present invention relates to the markers for acting on GIST tumor migration, belong to bio-medical analysis field.
Background technique
Gastrointestinal stromal tumor (Gastrointestinal stromal tumors, GIST) is between the most common gastrointestinal tract
Matter tumour just has 6.8 people to be checked out with GIST in annual every million crowd, and patient is that person in middle and old age are in the majority, there are also less than
1% GISTs age was at 20 years old or less.GIST is usually primary in stomach (68%) and small intestine (25-30%).Receptor tyrosine kinase
(Receptor tyrosine kinase, RTK)KITWith Platelet-derived growth factor α-receptor polypeptide (platelet-
Derived growth factor receptor alpha, PDGFRA) gene mutation be GIST occur with transfer it is main because
Element.Research has shown that GISTs has 85%KITMutation or 10-15%PDGFRAGene mutation.There are also 10-15% to be not presentKIT/ PDGFRAThe GISTs of mutation, often referred to as " wild type " GIST.Currently, the Main Diagnosis marker of GIST includes KIT
(CD117), PKC θ (PRKCQ), DOG1, CAII tetra-.
GIST experienced operative treatment → targeted therapy → complex treatment → individualized treatment of pure in recent decades
This series of fast development.Surgical resection therapy high recurrence rate, chemicotherapy is even more more harm than good, therefore tyrosine kinase inhibits
Agent TKI is the optimal selection of many GIST patients, and Imatinib (Imatinib, IM) is the choice drug for treating GIST.Due toKITWithPDGFRAGene high-frequency in GIST is mutated, and IM is good for most of GIST patient outcomes, but in medication 2-
There is drug resistance phenomenon to some extent in 3 Nian Houjun.
ACK1(Activated cdc42-associated kinase1) it is a kind of nonreceptor tyrosine kinase, it is located at thin
Cytoplasm, main conduction transmembrane protein (RTK) received extracellular signal to downstream passages.ACK1Gene is located at No. 3 chromosomes 29,
It encodes albumen and contains 1091 amino acid residues, molecular weight is 145 kDa.High table of the ACK1 in the kinds of tumor such as gastric cancer, lung cancer
The important function for reaching and tumour growth, migration and infiltration etc. being risen.AIM-100 is the selectively targeted inhibition of ACK1
Agent.
Summary of the invention
It is an object of the invention to diagnose for GIST and migration is inhibited to find new marker.The purpose of its method is by such as
Lower technical solution is completed, a kind of marker ACK1 and its application for gastrointestinal stromal tumors migration, the described mark
Object has a following two feature: first, compared with Carcinoma side normal tissue, ACK1 high expression and is activated in GIST cell for it；Second:
Targeted inhibition ACK1 can inhibit the migration of GIST cell.
As preferred: the step of detection ACK1 height in GIST cell is expressed and activated are as follows:
A. tumor tissues and cancer beside organism are crushed；The PBS of cell pre-cooling is cleaned one time；Protein lysis buffer is added to collect
Lysate is transferred in 1.5 mLEp pipes；It is put on the turntable of 4 DEG C of refrigerators and rotates overnight；13,000 rpm, 4 DEG C of centrifugations 30
min；Supernatant is moved in new centrifuge tube, volume is recorded.Protein concentration is measured, quantitatively to 2 μ g/ μ L and and Loading
Buffer is mixed.Protein sample is put into 100 DEG C of metal baths and boils 10 min, is centrifuged, PAGE gel electrophoresis;western
Blot, ECL developing solution A liquid and B liquid drip on film after mixing by 1:1, are imaged with ultra sensitive chemical luminescence imaging instrument；
B. co-immunoprecipitation: lytic cell, protein quantification such as step a；4 DEG C of mixing 30min of sepharose 4B are added, take
Reset and add and mix 2h into 4 DEG C of rotations of antibody, sepharose 4B is centrifuged to tube bottom by 4 DEG C of 3 min of centrifugation；Supernatant is carefully sucked,
Sepharose 4B is washed 3 times with lysis buffer；Add 20 μ L loading buffer, boiling water boiling 10 minutes；SDS-PAGE,
western blot。
As preferred: targeted inhibition ACK1 can inhibit the detection of the migration of GIST cell to include the following steps:
A. wound healing assay: in inoculating cell to six orifice plates, overnight incubation in cell incubator is placed；Second day with 100
μ L pipette tips vertically draw three vertical lines；It is rinsed 2 times with PBS, the culture medium culture of fresh drug containing is added；Choose the set time
Point is photographed to record, until control group wound healing.
B. matrigel transwel cell invasion is tested: 24 orifice plates of pre-cooling and cell, by the diluted base of serum free medium
Matter glue is laid on cell；To matrigel solidification inoculating cell in cell, it is small it is indoor be drug containing serum free medium, be in hole drug containing just
Normal culture medium；Small indoor culture medium is sucked after 48h, PBS cleans cell, and the fixed cell of methanol is added and dries；Crystal violet is added will
Cell dyeing is taken pictures.
ACK1 is a kind of nonreceptor tyrosine kinase, is located at cytoplasm, the received extracellular signal of main conduction transmembrane protein
To downstream passages.ACK1Gene is located at No. 3 chromosomes 29, and coding albumen contains 1091 amino acid residues, molecular weight 145
kDa.High expression of the ACK1 in the kinds of tumor such as gastric cancer, lung cancer and to tumour growth, migration and in terms of from
Important function.AIM-100 is the selectively targeted inhibitor of ACK1.
Detailed description of the invention
Fig. 1 is expression of the ACK1 in GIST tumor cell line,
Fig. 2 is expression of the ACK1 in GIST tumor tissues and cancer beside organism,
Fig. 3 is ACK1 and KIT co-immunoprecipitation, PY99 coloration result,
Fig. 4 is influence of the ACK1 targeted inhibition to GIST-T1 cell migration,
Fig. 5 is influence of the ACK1 targeted inhibition to GIST430 cell migration,
Fig. 6 is influence of the ACK1 targeted inhibition to GIST-T1 cell invasion,
Fig. 7 is influence of the ACK1 targeted inhibition to GIST430 cell invasion,
Fig. 8 is ACK1 targeted inhibition to GIST-T1,430 cell invasion quantitative analysis results.
Specific embodiment
The present invention is described in detail below in conjunction with specific embodiment and attached drawing, the life that the present invention selects in an implementation
Produce the commonly used equipment that equipment is all this field, it should be understood that it is described herein that specific examples are only used to explain the present invention, and
It is not used in the restriction present invention.
A kind of marker for GIST diagnosing tumor and migration, it is characterised in that in the content of described two aspects, point
It Bao Han not have the following steps:
Include following three step in content in terms of (1):
A. by GIST cell cracking, western blot；
B. tumor tissues and cancer beside organism are cracked, western blot；
C. ACK1 and KIT co-immunoprecipitation, PY99 dyeing；
Include following two steps in content in terms of (2):
D. by GIST cell inoculation into six orifice plates, second day, with 10 μ L pipette tips vertical scores, drug containing various concentration is used
Culture medium culture, fixed point is taken pictures daily, until control group wound healing；
E. GIST-T1, GIST430 matrigel transwell cell invasion are tested.
The method is characterized in that detecting ACK1 in cell strain, tumor sample and cancer beside organism by western blot first
In expression, then the activation of ACK1 is detected by ACK1 and KIT co-immunoprecipitation, finally by wound healing assay and matrigel
Cell invasion is experiments have shown that list targeted inhibition ACK1 can inhibit GIST cell migration；Specifically includes the following steps:
A. tumor tissues and cancer beside organism are broken；The PBS of cell pre-cooling is cleaned one time；Protein lysis buffer is added；It receives
Collection lysate is transferred in 1.5 mLEp pipes；It is put on the turntable of 4 DEG C of refrigerators and rotates overnight；13,000 rpm, 4 DEG C of centrifugations
30 min；Supernatant is moved in new centrifuge tube, volume is recorded.Protein concentration is measured, quantitatively to 2 μ g/ μ L and and Loading
Buffer is mixed.Protein sample is put into 100 DEG C of metal baths and boils 10 min, is centrifuged, PAGE gel electrophoresis;western
Blot, ECL developing solution A liquid and B liquid drip on film after mixing by 1:1, are imaged with ultra sensitive chemical luminescence imaging instrument.Cell strain is aobvious
Shadow result such as Fig. 1, GIST cell strain include GIST-T1, GIST882, GIST48, GIST430, GIST62, GIST522,
GIST48B, GIST430B, wherein GIST-T1, GIAT882 are point mutation of KIT, are IM sensitive cell strains；GIST48,
GIST430 is KIT point mutation twice, is IM drug-resistant cell strain；GIST62, GIST522, GIST48B, GIST430B KIT
Cell strain is lost in expression, to the anti-medicine of IM.Tumor tissues and cancer beside organism's developing result such as Fig. 2, wherein N is cancer beside organism, and T is swollen
Tumor tissue.This experiment is in triplicate.
The result shows that ACK1 high expression in GIST cell strain and tumor tissues, is not expressed in cancer beside organism.
B. co-immunoprecipitation: lytic cell, protein quantification such as step a；4 DEG C of mixing 30min of sepharose 4B are added, take
Reset and add and mix 2h into 4 DEG C of rotations of antibody, sepharose 4B is centrifuged to tube bottom by 4 DEG C of 3 min of centrifugation；Supernatant is carefully sucked,
Sepharose 4B is washed 3 times with lysis buffer；Add 20 μ L loading buffer, boiling water boiling 10 minutes；SDS-PAGE,
Western blot, as a result such as Fig. 3.This experiment is repeated twice.
The result shows that ACK1 is activated with phosphorylation form in GIST cell.
C. wound healing assay: in inoculating cell to six orifice plates, overnight incubation in cell incubator is placed；Second day use
100
μ L pipette tips vertically draw three vertical lines；It is rinsed 2 times with PBS, the culture medium culture of fresh drug containing is added；Choose the set time
Point is photographed to record, until control group wound healing, as a result such as Fig. 4, Fig. 5.This experiment is repeated 3 times.
The result shows that in IM sensitive cell strain GIST-T1 and IM drug-resistant cell strain GIST430, targeted inhibition
ACK1 can inhibit the migration of GIST cell.
D. matrigel transwel cell invasion is tested: 24 orifice plates of pre-cooling and cell, by the diluted base of serum free medium
Matter
Glue is laid on cell；To matrigel solidification inoculating cell in cell, small interior is drug containing serum free medium, is drug containing in hole
Normal incubation medium；Small indoor culture medium is sucked after 48h, PBS cleans cell, and the fixed cell of methanol is added and dries；Crystal violet is added
It by cell dyeing, takes pictures, as a result such as Fig. 6, Fig. 7；Staining cell is eluted with acetic acid and surveys the analysis of OD value, as a result such as Fig. 8.This
Experiment is repeated 3 times.
The result shows that single targeted inhibition ACK1 can inhibit GIST cell invasion.
Claims (3)
1. a kind of marker ACK1 and its application for gastrointestinal stromal tumors migration, it is characterised in that the described marker has
Following two feature: first, it is compared with Carcinoma side normal tissue, ACK1 high expression and activation in GIST cell；Second: targeting
Inhibit ACK1 that can inhibit the migration of GIST cell.
2. the marker ACK1 according to claim 1 for GIST diagnosing tumor and migration, it is characterised in that the inspection
Survey ACK1 high the step of expressing and activating in GIST cell are as follows:
A. tumor tissues and cancer beside organism are crushed；The PBS of cell pre-cooling is cleaned one time；Protein lysis buffer is added to collect
Lysate is transferred in 1.5 mLEp pipes；It is put on the turntable of 4 DEG C of refrigerators and rotates overnight；13,000 rpm, 4 DEG C of centrifugations 30
min；Supernatant is moved in new centrifuge tube, volume is recorded;
Protein concentration is measured, it is quantitative to be mixed to 2 μ g/ μ L and with Loading Buffer;Protein sample is put into 100 DEG C of metals
10 min are boiled in bath, are centrifuged, PAGE gel electrophoresis;After western blot, ECL developing solution A liquid and B liquid are mixed by 1:1
It drips on film, is imaged with ultra sensitive chemical luminescence imaging instrument；
B. co-immunoprecipitation: lytic cell, protein quantification such as step a；4 DEG C of mixing 30min of sepharose 4B are added, take
Reset and add and mix 2h into 4 DEG C of rotations of antibody, sepharose 4B is centrifuged to tube bottom by 4 DEG C of 3 min of centrifugation；Supernatant is carefully sucked,
Sepharose 4B is washed 3 times with lysis buffer；Add 20 μ L loading buffer, boiling water boiling 10 minutes；SDS-PAGE,
western blot。
3. the marker ACK1 according to claim 1 for GIST diagnosing tumor and migration, it is characterised in that targeting suppression
ACK1 processed can inhibit the detection of the migration of GIST cell to include the following steps:
A. wound healing assay: in inoculating cell to six orifice plates, overnight incubation in cell incubator is placed；Second day with 100
μ L pipette tips vertically draw three vertical lines；It is rinsed 2 times with PBS, the culture medium culture of fresh drug containing is added；Choose the set time
Point is photographed to record, until control group wound healing;
B. matrigel transwel cell invasion is tested: 24 orifice plates of pre-cooling and cell, by the diluted matrigel of serum free medium
It is laid on cell；To matrigel solidification inoculating cell in cell, small interior is drug containing serum free medium, is normally trained in hole for drug containing
Support base；Small indoor culture medium is sucked after 48h, PBS cleans cell, and the fixed cell of methanol is added and dries；Crystal violet is added by cell
Dyeing, takes pictures.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910261493.7A CN110031626A (en) | 2019-04-02 | 2019-04-02 | A kind of marker ACK1 and its application for gastrointestinal stromal tumors migration |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910261493.7A CN110031626A (en) | 2019-04-02 | 2019-04-02 | A kind of marker ACK1 and its application for gastrointestinal stromal tumors migration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110031626A true CN110031626A (en) | 2019-07-19 |
Family
ID=67237254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910261493.7A Pending CN110031626A (en) | 2019-04-02 | 2019-04-02 | A kind of marker ACK1 and its application for gastrointestinal stromal tumors migration |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110031626A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118389440A (en) * | 2024-06-28 | 2024-07-26 | 暨南大学附属第一医院（广州华侨医院） | Murine gastric stromal tumor cell strain |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101646427A (en) * | 2007-02-07 | 2010-02-10 | 史密丝克莱恩比彻姆公司 | The AKT activity inhibitor |
| CN101802618A (en) * | 2007-07-13 | 2010-08-11 | 普罗米修斯实验室股份有限公司 | Utilization is selected the lung cancer therapy medicine based on the array of antibody |
| US20110008347A1 (en) * | 2006-12-01 | 2011-01-13 | Agency For Science ,Technology And Research | Cancer-related protein kinases |
| CN104711341A (en) * | 2013-12-17 | 2015-06-17 | 上海市肿瘤研究所 | Application of DLK1 gene in preparation of gastrointestinal stromal tumor diagnostic reagent |
| KR20170076607A (en) * | 2015-12-23 | 2017-07-04 | 연세대학교 산학협력단 | Markers for diagnosing of gastrointestinal stromal tumors and method for diagnosing of gastrointestinal stromal tumors |
-
2019
- 2019-04-02 CN CN201910261493.7A patent/CN110031626A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110008347A1 (en) * | 2006-12-01 | 2011-01-13 | Agency For Science ,Technology And Research | Cancer-related protein kinases |
| CN101646427A (en) * | 2007-02-07 | 2010-02-10 | 史密丝克莱恩比彻姆公司 | The AKT activity inhibitor |
| CN101802618A (en) * | 2007-07-13 | 2010-08-11 | 普罗米修斯实验室股份有限公司 | Utilization is selected the lung cancer therapy medicine based on the array of antibody |
| CN104711341A (en) * | 2013-12-17 | 2015-06-17 | 上海市肿瘤研究所 | Application of DLK1 gene in preparation of gastrointestinal stromal tumor diagnostic reagent |
| KR20170076607A (en) * | 2015-12-23 | 2017-07-04 | 연세대학교 산학협력단 | Markers for diagnosing of gastrointestinal stromal tumors and method for diagnosing of gastrointestinal stromal tumors |
Non-Patent Citations (3)
| Title |
|---|
| 丁炯燕: "双靶向ACK1与KIT抑制胃肠道间质瘤增殖的作用机理研究", 《中国优秀博硕士学位论文全文数据库（硕士）》 * |
| 苏燕燕等: "胃肠道间质瘤的分子机制进展", 《国外医学.外科学分册》 * |
| 魏小栋等: "ACK1在肺鳞状细胞癌组织中的表达及其临床意义", 《中国生物制品学杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118389440A (en) * | 2024-06-28 | 2024-07-26 | 暨南大学附属第一医院（广州华侨医院） | Murine gastric stromal tumor cell strain |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lin et al. | Monitoring Tyrosinase Expression in Non‐metastatic and Metastatic Melanoma Tissues by Scanning Electrochemical Microscopy | |
| CN105866418B (en) | A kind of breast carcinoma three joint inspection diagnostic kit | |
| Mottaleb et al. | The Lundh test in the diagnosis of pancreatic disease: a review of five years' experience | |
| Yamamoto et al. | Evaluation of endoscopic ultrasound image quality is necessary in endosonographic assessment of early gastric cancer invasion depth | |
| Sun et al. | Expression of DOG1, CD117 and PDGFRA in gastrointestinal stromal tumors and correlations with clinicopathology | |
| CN108949997A (en) | A kind of lung cancer detection marker and diagnostic kit | |
| CN110031626A (en) | A kind of marker ACK1 and its application for gastrointestinal stromal tumors migration | |
| Rogge et al. | Evaluation of a new urease reagent strip for detection of Helicobacter pylori in gastric biopsy specimens. | |
| CN110187111B (en) | ELISA kit for screening early cardiac cancer | |
| RU2421149C2 (en) | Method of differential diagnostics of pancreatic cancer and chronic pancreatitis | |
| CN106290888B (en) | Detect antibody compositions and its application of ductal adenocarcinoma of pancreas immunohistochemical markers protein combination | |
| TWI798532B (en) | Use of kdm5a gene and atrx gene | |
| CN108931633B (en) | Gallbladder cancer diagnosis and prognosis judgment marker PIM1 | |
| CN107167604A (en) | Applications of the FLOT1 in as oophoroma biomarker | |
| Min et al. | Advancement of secretory breast carcinoma: a narrative review | |
| CN107144695B (en) | Application of the Arl13b albumen in cancer diagnosis | |
| JP4887505B2 (en) | Method for examining metastasis and invasiveness of cancer | |
| CN108203734A (en) | Application of the RHCG genes in treating cancer drug and diagnostic kit is prepared | |
| Saito et al. | Prognostic significance of lymph node dissection along the upper-third-stomach in patients with lower-third gastric cancer | |
| CN106383230B (en) | A kind of pulmonary cancer diagnosis kit | |
| Shui et al. | Relationship between cyclooxygenase-2 (COX-2) content and prognosis in nasopharyngeal carcinoma before and after radiochemotherapy | |
| CN110456072A (en) | The application of 1 α of regenerating islets original albumen and its detection method | |
| JP7246731B2 (en) | Pancreatic cancer prognostic marker, pancreatic cancer prognostic diagnosis kit and method for predicting pancreatic cancer prognosis | |
| CN109722480A (en) | A kind of non-small cell lung cancer detection kit and its application | |
| Kaulanjan-Checkmodine et al. | Pericytes from Infantile Hemangioma regulate vessels formation in vitro |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190719 |
|
| RJ01 | Rejection of invention patent application after publication |